Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline

Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.

MMatthew Bick DDavid Baker AAccipiter Bio FFlying Fish Partners